title: [ROS1-Translocations in Non-Small Cell Lung Cancer].
abstract: OBJECTIVE
  Summary of prevalence, testing and treatment approaches in patients with non-small cell lung cancer (NSCLC) and ROS1 activation.
  
  
  METHODS
  Internet-based search for clinical and preclinical studies as well as search for ongoing studies in web-based databases.
  
  
  RESULTS
  ROS1 translocations lead to tyrosine kinase activation and can be detected in 1 - 2% of all NSCLC and in 3 - 6% of pulmonary adenocarcinoma patients, respectively, using in situ hybridization techniques. RESULTS from phase I clinical studies using the ROS1 inhibitor crizotinib indicate response rates of 70 - 80% and a median progression-free survival of about 19 months. The therapy was generally well tolerated.
  
  
  CONCLUSIONS
  NSCLC harbouring ROS1-translocations can be treated with targeted therapy leading to promising response and survival in patients. Hence, these alterations should be included into current molecular testing panels in stage IV pulmonary adenocarcinomas.
authors.affiliation: Institut für Pathologie, Universität Heidelberg.
authors.forename: A
authors.initials: A
authors.lastname: Warth
authors.affiliation: Institut für Pathologie, Universität Heidelberg.
authors.forename: W
authors.initials: W
authors.lastname: Weichert
authors.affiliation: LungenClinic Großhansdorf, Abteilung für Thoraxonkologie.
authors.forename: M
authors.initials: M
authors.lastname: Reck
authors.affiliation: LungenClinic Großhansdorf, Abteilung für Thoraxonkologie.
authors.forename: N
authors.initials: N
authors.lastname: Reinmuth
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000453:epidemiology* / Q000235:genetics*; D019317:Evidence-Based Medicine; D005260:Female; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000453:epidemiology / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology* / Q000235:genetics*; D008297:Male; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D015995:Prevalence; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics; D012307:Risk Factors; D014178:Translocation, Genetic / Q000235:genetics*
chemical_list: D005819:Genetic Markers; D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; C062333:ROS1 protein, human